Decibel Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.09
- Today's High:
- $5.15
- Open Price:
- $5.09
- 52W Low:
- $1.61
- 52W High:
- $5.78
- Prev. Close:
- $5.13
- Volume:
- 39398
Company Statistics
- Market Cap.:
- $104.06 million
- Book Value:
- 2.953
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -28.17%
- Return on Equity TTM:
- -62.93%
Company Profile
Decibel Therapeutics Inc had its IPO on 2021-02-12 under the ticker symbol DBTX.
The company operates in the Healthcare sector and Biotechnology industry. Decibel Therapeutics Inc has a staff strength of 68 employees.
Stock update
Shares of Decibel Therapeutics Inc opened at $5.09 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.09 - $5.15, and closed at $5.14.
This is a +0.19% increase from the previous day's closing price.
A total volume of 39,398 shares were traded at the close of the day’s session.
In the last one week, shares of Decibel Therapeutics Inc have increased by +0.59%.
Decibel Therapeutics Inc's Key Ratios
Decibel Therapeutics Inc has a market cap of $104.06 million, indicating a price to book ratio of 0.6679 and a price to sales ratio of 0.
In the last 12-months Decibel Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-62624000. The EBITDA ratio measures Decibel Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Decibel Therapeutics Inc’s operating margin was 0% while its return on assets stood at -28.17% with a return of equity of -62.93%.
In Q1, Decibel Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Decibel Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Decibel Therapeutics Inc’s profitability.
Decibel Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5522. Its price to sales ratio in the trailing 12-months stood at 0.
Decibel Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $110.45 million
- Total Liabilities
- $23.18 million
- Operating Cash Flow
- $20.32 million
- Capital Expenditure
- $266000
- Dividend Payout Ratio
- 0%
Decibel Therapeutics Inc ended 2024 with $110.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $110.45 million while shareholder equity stood at $69.84 million.
Decibel Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $23.18 million in other current liabilities, 25000.00 in common stock, $-290821000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.07 million and cash and short-term investments were $87.94 million. The company’s total short-term debt was $3,588,000 while long-term debt stood at $0.
Decibel Therapeutics Inc’s total current assets stands at $95.87 million while long-term investments were $0 and short-term investments were $49.88 million. Its net receivables were $4.40 million compared to accounts payable of $1.28 million and inventory worth $0.
In 2024, Decibel Therapeutics Inc's operating cash flow was $20.32 million while its capital expenditure stood at $266000.
Comparatively, Decibel Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.14
- 52-Week High
- $5.78
- 52-Week Low
- $1.61
- Analyst Target Price
- $13.17
Decibel Therapeutics Inc stock is currently trading at $5.14 per share. It touched a 52-week high of $5.78 and a 52-week low of $5.78. Analysts tracking the stock have a 12-month average target price of $13.17.
Its 50-day moving average was $4.06 and 200-day moving average was $3.55 The short ratio stood at 6.83 indicating a short percent outstanding of 0%.
Around 1499.4% of the company’s stock are held by insiders while 7072.3% are held by institutions.
Frequently Asked Questions About Decibel Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company’s product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.